All In Biotech

Drug Trial Radar · NCT07279935

Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.

Biomarker-Directed Treatment in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC: A Prospective, Multi-cohort, Interventional Study (REVIVE)

Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 26, 2026

Primary completion

May 18, 2030

Study completion May 18, 2030

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed as a multi-cohort trial based on various patient biomarkers study with the potential to include new study treatment in the future. EGFR-sensitive mutation-positive patients with distant recurrence after adjuvant osimertinib treatment for EGFRm resectable SIB-IIIA NSCLC and scheduled to receive osimertinib plus chemotherapy will be enrolled in cohort 1. In this cohort, approximately 100 patients will be recruited from 25 sites in China. The enrolment period is planned to be approximately 16 months.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • Osimertinib+cisplatin or carboplatin + pemetrexed EditDrug

    Cohort 1 treated with osimertinib 80 mg once daily (QD) in combination with platinum-based chemotherapy cisplatin \[75 mg/m2\] or carboplatin \[AUC5\]) plus pemetrexed (500 mg/m2) on Day 1 every 3 weeks (Q3W) for 4 cycles, followed by osimertinib QD and pemetrexed Q3W till RECIST 1.1-defined progression or until another discontinuation criterion is met.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess the efficacy of osimertinib + chemotherapy by evaluation of PFS in patients who had distant recurrence after adjuvant osimertinib.Time frame: Approximately 52 months

Locations

32 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Chengdu, China · Recruiting

  • Research Site

    Chongqing, China · Recruiting

  • Research Site

    Fuzhou, China · Recruiting

  • Research Site

    Fuzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Guangzhou, China · Withdrawn

  • Research Site

    Guangzhou, China · Recruiting

  • Research Site

    Hangzhou, China · Recruiting

  • Research Site

    Hefei, China · Recruiting

  • Research Site

    Hefei, China · Withdrawn

  • Research Site

    Jinan, China · Withdrawn

  • Research Site

    Jinan, China · Recruiting

  • Research Site

    Kunming, China · Withdrawn

  • Research Site

    Nanchang, China · Recruiting

  • Research Site

    Nanjing, China · Withdrawn

  • Research Site

    Nanjing, China · Recruiting

  • Research Site

    Ningbo, China · Recruiting

  • Research Site

    Shanghai, China · Recruiting

  • Research Site

    Shanghai, China · Withdrawn

  • Research Site

    Shanghai, China · Withdrawn

  • Research Site

    Shenyang, China · Recruiting

  • Research Site

    Shenyang, China · Recruiting

  • Research Site

    Tianjin, China · Recruiting

  • Research Site

    Wuhan, China · Recruiting

  • Research Site

    Wuhan, China · Recruiting

  • Research Site

    Xi'an, China · Recruiting

  • Research Site

    Xi'an, China · Withdrawn

  • Research Site

    Zhengzhou, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.